(NASDAQ: ORKA) Oruka Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Oruka Therapeutics's earnings in 2026 is -$132,886,000.On average, 14 Wall Street analysts forecast ORKA's earnings for 2026 to be -$174,978,993, with the lowest ORKA earnings forecast at -$188,167,965, and the highest ORKA earnings forecast at -$162,260,109. On average, 14 Wall Street analysts forecast ORKA's earnings for 2027 to be -$186,784,182, with the lowest ORKA earnings forecast at -$265,381,716, and the highest ORKA earnings forecast at -$124,441,129.
In 2028, ORKA is forecast to generate -$240,519,974 in earnings, with the lowest earnings forecast at -$401,641,276 and the highest earnings forecast at -$178,666,873.